Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.67 and traded as low as $0.50. Northwest Biotherapeutics shares last traded at $0.50, with a volume of 1,067,559 shares traded.
Northwest Biotherapeutics Stock Performance
The stock’s 50 day moving average price is $0.54 and its two-hundred day moving average price is $0.66. The firm has a market capitalization of $602.92 million, a price-to-earnings ratio of -8.35 and a beta of -0.68.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last issued its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.45 million for the quarter.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Further Reading
- Five stocks we like better than Northwest Biotherapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- United Airlines Soars on Earnings Beat
- 3 Monster Growth Stocks to Buy Now
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is the Shanghai Stock Exchange Composite Index?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
